In pre­lim­i­nary read­out, GSK notch­es win for meningo­coc­cal vac­cine

GSK said its next-gen­er­a­tion meningo­coc­cal vac­cine is just as good as cur­rent­ly avail­able vac­cines Bexsero and Men­veo in peo­ple be­tween the ages of 10 and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.